ARNA Arena Pharmaceuticals Inc

Price (delayed)

$61.31

Market cap

$3.74B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$8.19

Enterprise value

$3.27B

Arena Pharmaceuticals, Inc. is a biopharmaceutical company founded in 1997 and located in San Diego, California. The company has small molecule drugs in development for possible clinical utility in multiple ...

Highlights
ARNA's debt is down by 9% YoY and by 2.4% from the previous quarter
The revenue has dropped by 99% year-on-year
The gross profit has plunged by 99% YoY

Key stats

What are the main financial stats of ARNA
Market
Shares outstanding
61.07M
Market cap
$3.74B
Enterprise value
$3.27B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.83
Price to sales (P/S)
65,382.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
57,434.99
Earnings
Revenue
$57,000
EBIT
-$479.77M
EBITDA
-$475.89M
Free cash flow
-$395.68M
Per share
EPS
-$8.19
Free cash flow per share
-$6.51
Book value per share
$16
Revenue per share
$0
TBVPS
$17.84
Balance sheet
Total assets
$1.08B
Total liabilities
$113.58M
Debt
$43.5M
Equity
$971.08M
Working capital
$925.6M
Liquidity
Debt to equity
0.04
Current ratio
15.28
Quick ratio
14.98
Net debt/EBITDA
0.99
Margins
EBITDA margin
-834,889.5%
Gross margin
100%
Net margin
-849,317.5%
Operating margin
-895,591.2%
Efficiency
Return on assets
-40.9%
Return on equity
-45%
Return on invested capital
-62.6%
Return on capital employed
-47%
Return on sales
-841,703.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ARNA stock price

How has the Arena Pharmaceuticals stock price performed over time
Intraday
2.05%
1 week
2.42%
1 month
16.94%
1 year
-16.8%
YTD
-20.2%
QTD
-10.1%

Financial performance

How have Arena Pharmaceuticals's revenue and profit performed over time
Revenue
$57,000
Gross profit
$57,000
Operating income
-$510.49M
Net income
-$484.11M
Gross margin
100%
Net margin
-849,317.5%
The revenue has dropped by 99% year-on-year
The gross profit has plunged by 99% YoY
The operating income has declined by 40% year-on-year and by 12% since the previous quarter
Arena Pharmaceuticals's net income has decreased by 40% YoY and by 14% from the previous quarter

Growth

What is Arena Pharmaceuticals's growth rate over time

Valuation

What is Arena Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.83
P/S
65,382.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
57,434.99
The EPS has decreased by 19% YoY and by 11% QoQ
The P/B is 64% less than the 5-year quarterly average of 10.5 and 6% less than the last 4 quarters average of 4.0
ARNA's equity is down by 22% YoY and by 11% QoQ
The revenue has dropped by 99% year-on-year
ARNA's price to sales (P/S) is 60% more than its last 4 quarters average of 40002.6

Efficiency

How efficient is Arena Pharmaceuticals business performance
ARNA's return on invested capital has dropped by 70% year-on-year and by 24% since the previous quarter
ARNA's ROE is down by 45% YoY and by 22% from the previous quarter
ARNA's ROA is down by 43% year-on-year and by 21% since the previous quarter
The ROS has decreased by 15% QoQ

Dividends

What is ARNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARNA.

Financial health

How did Arena Pharmaceuticals financials performed over time
ARNA's current ratio is down by 47% YoY and by 35% from the previous quarter
The quick ratio has declined by 46% year-on-year and by 35% since the previous quarter
ARNA's debt is 96% less than its equity
ARNA's equity is down by 22% YoY and by 11% QoQ
ARNA's debt is down by 9% YoY and by 2.4% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.